Clinical Trial Update: A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating alternative dosing rate of rituximab in previously untreated diffuse large B-cell lymphoma and follicular lymphoma; results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Hodgkin's Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2012-06-26